Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe? ; volume:6 ; number:1 ; day:5 ; month:9 ; year:2011 ; pages:1-11 ; date:12.2011
Orphanet journal of rare diseases ; 6, Heft 1 (5.9.2011), 1-11, 12.2011
- Creator
-
Brabers, Anne EM
- Contributor
-
Moors, Ellen HM
van Weely, Sonja
de Vrueh, Remco LA
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-6-59
- URN
-
urn:nbn:de:1111-2016050119913
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brabers, Anne EM
- Moors, Ellen HM
- van Weely, Sonja
- de Vrueh, Remco LA
- SpringerLink (Online service)
Other Objects (12)
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry
Publication of clinical trials on medicinal products: follow-up on trials authorized in Hungary
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry
Publication of clinical trials on medicinal products: follow-up on trials authorized in Hungary
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry